New application in the RIM suite to unify publishing capabilities and content management,
from planning through archival, within a single cloud platform
Pleasanton, CA - Veeva Systems today announced Veeva Vault Submissions Publishing, a new cloud application that seamlessly incorporates publishing capabilities within Veeva Vault RIM to speed regulatory submission delivery. The addition of Vault Submissions Publishing unifies publishing capabilities and enterprise content management to streamline end-to-end submission development. Now life sciences companies can plan, review, publish, archive, and validate submissions within a single cloud platform.
Traditionally, regulatory submissions are created with disparate systems for content management and publishing. Working with separate systems requires file transfers and impedes the publishing team’s visibility into document readiness, making it difficult to effectively plan and allocate resources.
“Submission planning, registration tracking, document management, and publishing are all within one end-to-end process,” said Steve Gens, managing partner at Gens and Associates. “Having publishing within a set of unified regulatory capabilities can reduce cycle times and improve productivity throughout the entire submission development process.”
Veeva Vault Submissions Publishing empowers publishing teams to perform activities during document authoring, formatting, and reviews. This enables a continuous publishing process instead of waiting for the submission plan and documents to be finalized. With activities such as document hyperlinking and validation now moved upstream and automated, teams can complete work faster and speed submission development.
“The industry struggles with disjointed systems that force regulatory teams to duplicate data, documents, and effort,” said Frank Bosley, vice president, global head of regulatory operations at The Medicines Company. “A unified RIM approach like Veeva's can streamline submission preparation and enable sponsors to reduce risk and delays.”
Veeva Vault Submissions Publishing together with Vault Registrations, Vault Submissions, and Vault Submissions Archive delivers a unified RIM suite for seamless information and traceability throughout RIM processes.
“RIM transformation is gaining considerable momentum as companies seek greater visibility and global alignment across regulatory,” said John Lawrie, vice president, Veeva Vault RIM, at Veeva. “Now, with end-to-end submission development, regulatory can speed submission delivery and gain complete traceability between source documents, filed dossiers, and related product registrations.”
Veeva Vault Submissions Publishing is planned for availability in early 2018.
Additional Information
For more on Veeva Vault Submissions Publishing: veeva.com/Publishing
For more on Veeva Vault RIM: veeva.com/RIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystemsAbout Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 475 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.